Discover comprehensive details about Safinamide, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Results of the SAFINONMOTOR open-label study found that safinamide was safe and effective in improving pain of patients with Parkinson disease at 6 months. Safinamide may significantly improve pain in ...

Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or ...

Safinamide belongs to a class of drugs called monoamine oxidase type B inhibitors and is used in conjunction with levodopa to manage OFF periods. Treatment with safinamide 50 mg may significantly ...

• Safinamide comes as a tablet to be taken by mouth either with or without food once daily. • It should be swallowed with sufficient quantity of water usually around the same time each day. • The ...

April 12, 2011 (Honolulu, Hawaii) — A phase 3 clinical trial assessing the efficacy and safety of a safinamide add-on in patients with idiopathic Parkinson's disease has returned encouraging results.

Zambon S.p.A., an International Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases, and its partner Newron Pharmaceuticals S.p.A. (“Newron”), a research and ...

Please provide your email address to receive an email when new articles are posted on . Between March 5, 2009 and February 23, 2012, Schapira and colleagues performed a randomized, double-blind ...

Safinamide sets the stage Over the next 12-24 months, Newron Pharma, (NWRM.SW) could transition to a company with a marketed asset and a pipeline of orphan drugs in pivotal development, which it could ...

Safinamide (trade name: Xadago) has been available since February 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson disease in adults. In combination with levodopa alone or ...

Relevant study data were not considered / analyses in the dossier were incomplete regarding serious side effects in the comparator therapy, long-term data and other aspects Institute for Quality and ...

Regarding Safinamide in Parkinson's disease, reviewers state that since since relevant study data were not considered, analyses in the dossier were incomplete regarding serious side effects in the ...